# OnCo record cml-chronic-phase (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cml-chronic-phase/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cml-chronic-phase" ;
  schema:name "Chronic myeloid leukaemia, chronic phase"@en ;
  schema:alternateName "CML-CP"@en, "Chronic-phase CML"@en, "Newly diagnosed Ph-positive CML"@en, "BCR::ABL1-positive chronic phase"@en ;
  schema:description "Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."@en ;
  schema:url <https://onco.cc/cancers/cml-chronic-phase/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/mrd-kinetics-models/>, <https://onco.cc/technologies/cytogenetics-fish/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:pathways <https://onco.cc/pathways/bcr-abl1-signalling/>, <https://onco.cc/pathways/cml-signalling/> ;
  onco:terms <https://onco.cc/terms/molecular-response/>, <https://onco.cc/terms/philadelphia-chromosome/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/mrd/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-iris-imatinib-nejm-2003/>, <https://onco.cc/key-papers/paper-druker-imatinib-phase1-nejm-2001/> ;
  onco:pipeline <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/olverembatinib/>, <https://onco.cc/drugs/radotinib/>, <https://onco.cc/trials/nct04971226/>, <https://onco.cc/trials/nct05456191/>, <https://onco.cc/trials/nct06423911/>, <https://onco.cc/trials/nct06163430/> ;
  onco:standardOfCare <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/trials/nct04971226/>, <https://onco.cc/trials/nct05456191/>, <https://onco.cc/terms/molecular-response/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/olverembatinib/>, <https://onco.cc/drugs/radotinib/>, <https://onco.cc/trials/nct06423911/>, <https://onco.cc/trials/nct03459534/>, <https://onco.cc/trials/nct05384587/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/molecular-response/>, <https://onco.cc/technologies/mrd-kinetics-models/> .